0000899243-20-014945.txt : 20200602
0000899243-20-014945.hdr.sgml : 20200602
20200602200207
ACCESSION NUMBER: 0000899243-20-014945
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200601
FILED AS OF DATE: 20200602
DATE AS OF CHANGE: 20200602
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Weissman James B
CENTRAL INDEX KEY: 0001598480
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36281
FILM NUMBER: 20938644
MAIL ADDRESS:
STREET 1: C/O DICERNA PHARMACEUTICALS, INC.
STREET 2: 33 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001399529
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205993609
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 33 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617 621 8097
MAIL ADDRESS:
STREET 1: 33 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-01
0
0001399529
Dicerna Pharmaceuticals Inc
DRNA
0001598480
Weissman James B
C/O DICERNA PHARMACEUTICALS, INC.
33 HAYDEN AVENUE
LEXINGTON
MA
02421
0
1
0
0
Chief Operating Officer & EVP
Common Stock
2020-06-01
4
M
0
4360
2.97
A
26220
D
Common Stock
2020-06-01
4
S
0
4360
21.0567
D
21860
D
Employee Stock Option (Right to Buy)
2.97
2020-06-01
4
M
0
4360
0.00
D
2027-01-03
Common Stock
4360
30340
D
The reporting person sold an aggregate of 4,360 shares of common stock on June 1, 2020 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 0.57% of 765,958 shares of common stock, which is the number of shares of common stock owned by the reporting person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the reporting person as of the date of this report.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.77 to $21.61, inclusive. The reporting person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
The options vest in 48 monthly installments over the four-year period starting on the last day of January 2017, subject in each case to the reporting person's continued service with the issuer through the applicable vesting date.
/s/ John B. Green, attorney-in-fact
2020-06-02